Everything About Palopegteriparatide

Palopegteriparatide is a long-acting prodrug of parathyroid hormone designed for once-weekly subcutaneous administration in hypoparathyroidism. By providing sustained physiological systemic exposure, it normalizes serum calcium and urinary calcium excretion while eliminating the erratic fluctuations associated with conventional twice-daily short-acting teriparatide injections. Clinical trials demonstrate effective maintenance of normocalcemia independent of high-dose oral calcium and active vitamin D supplementation, significantly reducing both acute symptom burden and long-term renal complications such as nephrocalcinosis and hypercalciuria inherent to traditional management regimens.